Amneal Pharmaceuticals (AMRX) Q1 Earnings Beat Estimates

Core Viewpoint - Amneal Pharmaceuticals reported quarterly earnings of $0.21 per share, exceeding the Zacks Consensus Estimate of $0.15 per share, and showing an increase from $0.14 per share a year ago, indicating a 40% earnings surprise [1][2] Financial Performance - The company posted revenues of $695.42 million for the quarter ended March 2025, which was 2.71% below the Zacks Consensus Estimate, but an increase from $659.19 million year-over-year [2] - Over the last four quarters, Amneal has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times as well [2] Stock Performance - Amneal shares have declined approximately 2.3% since the beginning of the year, while the S&P 500 has decreased by 4.7% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.18 on revenues of $767.5 million, and for the current fiscal year, it is $0.68 on revenues of $3.03 billion [7] - The outlook for the Medical - Drugs industry, where Amneal operates, is favorable, ranking in the top 26% of over 250 Zacks industries, suggesting potential for outperformance [8]